论文部分内容阅读
目的：观察吡柔比星对急性非淋巴细胞白血病的疗效及副作用。方法：用吡柔比星（２０ｍｇ／ｍ２，ｉｖ，ｑｄ×３ｄ）与阿糖胞苷［１００ｍｇ／ｍ２，ｉｖ，ｑ１２ｈ×（７～１０ｄ）］联合治疗急性非淋巴细胞白血病３１例（男性２０例，女性１１例，年龄３７±ｓ９ａ），另设柔红霉素（４０ｍｇ／ｍ２，ｉｖ，ｑｄ×３ｄ）与阿糖胞苷（剂量同上）治疗急性非淋巴细胞白血病２８例（男性１６例，女性１２例，年龄４２±１４ａ）作为对照。结果：治疗组完全缓解１３例，部分缓解６例，总有效率６１％，高于对照组（４６％）（Ｐ＞０．０５），副作用较对照组轻。结论：吡柔比星对治疗急性非淋巴细胞白血病是值得推广的新药。
Objective: To observe the efficacy and side effects of pirarubicin in acute non-lymphocytic leukemia. Methods: 31 cases of acute non-lymphocytic leukemia were treated with pirarubicin (20mg / m2, iv, qd × 3d) and cytarabine [100mg / m2, iv, q12h × (N = 11, females, age 37 ± s9a) and another 28 patients with acute non-lymphocytic leukemia (40 males, 40 mg / m2, iv, qd × 3d) and cytarabine , 12 females, age 42 ± 14a) as a control. Results: In the treatment group, 13 cases were completely relieved and 6 cases partially relieved. The total effective rate was 61%, which was higher than that of the control group (46%) (P> 0.05). The side effects were lighter than those of the control group. Conclusion: Pirarubicin is a new drug worthy of promotion in the treatment of acute non-lymphocytic leukemia.